A common feature pharmacophore for FDA-approved drugs inhibiting the Ebola virus [v1; ref status: indexed, http://f1000r.es/4qh]
We are currently faced with a global infectious disease crisis which has been anticipated for decades. While many promising biotherapeutics are being tested, the search for a small molecule has yet to deliver an approved drug or therapeutic for the Ebola or similar filoviruses that cause haemorrhagi...
Main Authors: | Sean Ekins, Joel S. Freundlich, Megan Coffee |
---|---|
Format: | Article |
Language: | English |
Published: |
F1000 Research Ltd
2014-11-01
|
Series: | F1000Research |
Subjects: | |
Online Access: | http://f1000research.com/articles/3-277/v1 |
Similar Items
-
A common feature pharmacophore for FDA-approved drugs inhibiting the Ebola virus [v2; ref status: indexed, http://f1000r.es/4wt]
by: Sean Ekins, et al.
Published: (2014-12-01) -
Monitoring drug promiscuity over time [v1; ref status: indexed, http://f1000r.es/4bh]
by: Ye Hu, et al.
Published: (2014-09-01) -
Monitoring drug promiscuity over time [v2; ref status: indexed, http://f1000r.es/4oa]
by: Ye Hu, et al.
Published: (2014-11-01) -
Finding small molecules for the ‘next Ebola’ [v1; ref status: indexed, http://f1000r.es/542]
by: Sean Ekins, et al.
Published: (2015-02-01) -
Finding small molecules for the ‘next Ebola’ [v2; ref status: indexed, http://f1000r.es/5lb]
by: Sean Ekins, et al.
Published: (2015-07-01)